Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience

Background: Mepolizumab and benralizumab are monoclonal antibodies directed against anti-IL-5 and anti-IL5R, respectively, and their use reduces the exacerbation rate and maintains oral corticosteroid requirements in severe eosinophilic asthma. Previous studies have tested the therapeutic switch bet...

Descripción completa

Detalles Bibliográficos
Autores principales: Scioscia, Giulia, Tondo, Pasquale, Nolasco, Santi, Pelaia, Corrado, Carpagnano, Giovanna Elisiana, Caiaffa, Maria Filomena, Valenti, Giuseppe, Maglio, Angelantonio, Papia, Francesco, Triggiani, Massimo, Crimi, Nunzio, Pelaia, Girolamo, Vatrella, Alessandro, Foschino Barbaro, Maria Pia, Crimi, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342237/
https://www.ncbi.nlm.nih.gov/pubmed/37445397
http://dx.doi.org/10.3390/jcm12134362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342237/
https://www.ncbi.nlm.nih.gov/pubmed/37445397
http://dx.doi.org/10.3390/jcm12134362

Ejemplares similares